Harvard Bioscience logo

Harvard Bioscience (HBIO) Q1 2026 Earnings

HBIO·Reported May 12, 2026·Before market open

Harvard Bioscience reported Q1 2026 revenue of $20.8M (-4.7% YoY), missed analyst consensus of $21.2M by $445.0K. Diluted EPS came in at $-0.33 (-3200.0% YoY), beat the $-0.62 consensus by $0.29.

Revenue
$20.8Mmissed by $445.0K
Consensus: $21.2M
Diluted EPS
$-0.33beat by $0.29
Consensus: $-0.62
SEC

SEC Filings

Earnings release8-K · 0001171843-26-003270
Quarterly report10-Q · 0001171843-26-003311

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Harvard Bioscience's Q1 2026 earnings report.

Harvard Bioscience (HBIO) reported Q1 2026 earnings on May 12, 2026 before market open.

Harvard Bioscience reported revenue of $20.8M and diluted EPS of $-0.33 for Q1 2026.

Revenue missed the consensus estimate of $21.2M by $445.0K. EPS beat the consensus estimate of $-0.62 by $0.29.

Compared to the same quarter a year prior, revenue declined 4.7% from $21.8M a year earlier and diluted EPS declined 3200.0% from $-0.01.

You can read the 8-K earnings release (0001171843-26-003270) and the 10-Q periodic report (0001171843-26-003311) directly on SEC EDGAR. The filing index links above go to sec.gov.